MedTrace Logo

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT05883644 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2026-04-30

No results posted yet for this study

Summary

This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.

Conditions

Interventions

DRUG

Durvalumab

Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion

DRUG

Tremelimumab

Participants will receive single dose of 300 mg through IV infusion at Day 1

Sponsors & Collaborators

Principal Investigators

  • Stephen Chan, MD · Department of Clinical Oncology, Chinese University of Hong Kong

  • Lorenza Rimassa, MD · Humanitas Cancer Centre, IRCCS Humanitas Research Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-27
Primary Completion
2026-03-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Hong Kong
  • Italy
  • Japan
  • Singapore
  • South Korea
  • Spain
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05883644 on ClinicalTrials.gov